Iparomlimab and tuvonralimab (QL1706) combined definitive chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (QL1706-IIT-02): a single arm, phase 2 trial.

The analysis indicated that the present cohort showed a trend toward improved PFS and significantly better OS than those treated with definitive CRT ( Figure S6 ).

also in 53,322 other papers

Variables (e.g., as age, sex, smoking history, and drinking history) did not reach statistical significance. cTNM stage, CPS, and TMB were subsequently entered into the multivariate analyses.

also in 111,027 other papers

Within our institution, OS improved and PFS showed a favorable trend in the present cohort relative to PSM patients receiving definitive CRT ( Figure S6 ); however, no significant differences in PFS or OS were observed between the present cohort and the camrelizumab plus definitive CRT cohort ( NCT03671265 ), 7 though this comparison is limited by the latter's smaller sample size (n = 20) and the use of a higher radiotherapy dose (60 Gy).

also in 1,335 other papers